Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis.

E tanercept, a soluble tumour necrosis factor a (TNFa) receptor fusion protein, may be combined with methotrexate (MTX) in severe rheumatoid arthritis (RA). Etanercept is generally given to patients treated with MTX who have an inadequate response. However, MTX could be introduced to patients who have already been treated with etanercept and who initially… CONTINUE READING